Abstract | BACKGROUND: OBJECTIVE: To evaluate the prevalence of cardiovascular adverse events among patients with cancer treated with monoclonal antibodies in Saudi Arabia. METHODS: This is a retrospective study conducted in a tertiary care hospital, Riyadh, Saudi Arabia. Data were obtained from an electronic medical record of patients with cancer treated with one of the selected monoclonal antibodies, who met the inclusion criteria between January 2005 until June 2015 and have been followed up for at least one year. Patients were stratified into groups according to monoclonal antibodies treatment: trastuzumab, bevacizumab, pertuzumab, and combined mAbs. RESULTS: A total of 1067 patient were included in the study, within the pre-determined study period. The prevalence of cardiovascular disease among patients with cancer treated with monoclonal antibodies was 16.3%. The prevalence of heart failure was relatively higher in the trastuzumab group (46/626 patients, 7.3%). Among 418 patients treated with bevacizumab, hypertension was the most frequent adverse event, reported in 38 patients (9.1%), followed by thromboembolism reported in 27 patients (6.5%). Treatment discontinuation owing to cardiovascular adverse events was reported in 42/1,067 patients (3.9%). CONCLUSION AND RELEVANCE: Prevalence of antineoplastic monoclonal antibody induced cardiovascular adverse events among patients with cancer is substantially high in Saudi Arabia. There is an urgent need to streamline the practice for identifying high risk patients and flexible referral system for cardio-oncology care.
|
Authors | Abdulrazaq S Al-Jazairi, Nahlah Bahammam, Dhai Aljuaid, Lama Almutairi, Shroog Alshahrani, Norah Albuhairan, Peter M B Cahusac, Ghazwa B Korayem |
Journal | Cardio-oncology (London, England)
(Cardiooncology)
Vol. 9
Issue 1
Pg. 35
(Sep 25 2023)
ISSN: 2057-3804 [Electronic] England |
PMID | 37749652
(Publication Type: Journal Article)
|
Copyright | © 2023. BioMed Central Ltd., part of Springer Nature. |